<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02123667</url>
  </required_header>
  <id_info>
    <org_study_id>CCD-01535AC1-01</org_study_id>
    <secondary_id>CCD-01535AC1-01</secondary_id>
    <nct_id>NCT02123667</nct_id>
  </id_info>
  <brief_title>AssessmenT of smalL Airways involvemeNT In aSthma (ATLANTIS)</brief_title>
  <acronym>ATLANTIS</acronym>
  <official_title>AssessmenT of smalL Airways involvemeNT In aSthma (ATLANTIS); Multinational, Multicentre, Non-pharmacological Intervention, Cross-sectional and Longitudinal Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chiesi Farmaceutici S.p.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chiesi Farmaceutici S.p.A.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multinational, multicentre, non-pharmacological intervention, cross-sectional and
      longitudinal study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Large non pharmacological studies on Small Airways Disease
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 2014</start_date>
  <completion_date type="Anticipated">January 2018</completion_date>
  <primary_completion_date type="Actual">February 28, 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the role of small airways abnormalities in the clinical manifestations of asthma.</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">900</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Asthmatic patients</arm_group_label>
    <description>asthmatic patients 18 to 65</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy volunteers</arm_group_label>
    <description>Volunteers 18 to 65</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Optional bronchoscopy with endobronchial and trans-bronchial biopsy will be applicable in
      selected sites only in EU and US. Total number of inflammatory cells and quantification of
      specific cells including eosinophils, T cells and macrophages will be performed. Gene
      expression profiles (including RNA) will be performed at a later date for future analysis on
      the pathobiology of asthma which will be defined in future specific protocols
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        900 subjects divided into 800 asthmatic patients and 100 healthy controls will be included.
        Recruitment will be balanced, at the extent possible, in order to achieve at least &gt; 150
        patients each for steps 1 - 4 and &gt; 50 patients for step 5 as indicated in the
        international guidelines (GINA 2012) on the basis of their previous therapy. The 150
        healthy controls will be recruited on the basis of absence of respiratory symptoms, airway
        obstruction and hyper responsiveness.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Asthmatic patient inclusion criteria

          1. Male or female patients aged ≥ 18 and ≤ 65 years, who have signed an Informed Consent
             form

          2. Clinical diagnosis of asthma f

               1. Positive response to methacholine challenge test

               2. Positive response to a reversibility test or

               3. Peak Flow variability (i.e. highest - lowest PEF over the day/mean value of the
                  two, × 100) &gt; 20% or

               4. Documented response (defined as ΔFEV1 ≥ 12% and ≥ 200 mL) after a cycle (e.g., 4
                  weeks) of regular maintenance anti-asthma treatment.

          3. Patients with stable asthma.

          4. Current smoker, ex-smoker or lifelong non-smoker Healthy subject inclusion criteria

        1. Male or female patients aged ≥ 18 and ≤ 65 years 2. No clinical history of asthma or
        COPD 3. Current smoker, ex-smoker or lifelong non-smokers 4. Normal spirometry 5. Normal
        airways responsiveness Asthmatic patient exclusion criteria

          1. Cigarette smoking &gt; 10 packyears

          2. diagnosis of COPD

          3. Asthma exacerbation in the 8 weeks prior to baseline visit

          4. Clinical or functional uncontrolled respiratory, haematological, immunologic, renal,
             neurologic, hepatic, endocrinal or other disease, or any condition that might
             compromise the results or interpretation of the study.

          5. Pregnant or lactating women

          6. Participation in an interventional clinical trial &lt;12 weeks preceding baseline visit

          7. Inability to comply with study procedures.

          8. Alcohol or drug abuse. Healthy subject exclusion criteria

        1. Cigarette smoking history &gt; 10 packyears 2. Diagnosed upper and/or lower respiratory
        disease(s). 3. Clinical or functional uncontrolled haematological, immunologic, renal,
        neurologic, hepatic, endocrinal or other disease, or any condition that mightp compromise
        the results or interpretation of the study.

        4. Pregnant or lactating women 5. Participation in an interventional clinical trial &lt;12
        weeks preceding baseline visit 6. Inability to comply with study procedures. 7. Alcohol or
        drug abuse.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Monica Kraft, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dirkje S Postma, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Medical Center Groningen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chiesi Clinical Trial Site #0503</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chiesi Clinical Trial Site #0502</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chiesi Clinical Trial Site #0504</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chiesi Clinical Trial Site #0501</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prof. Dr. Emilio Pizzichini</name>
      <address>
        <city>Florianópolis</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prof. Dr. Alberto Cukier</name>
      <address>
        <city>São Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prof. Dr. Rafael Stelmach</name>
      <address>
        <city>São Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chiesi Clinical Trial Site #0201</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2X 2P4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gao</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yuanlin Song</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032,</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Qingling Zhang</name>
      <address>
        <city>Hangzhou</city>
        <zip>510120</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chiesi Clinical Trial Site #0303</name>
      <address>
        <city>Grosshansdorf</city>
        <zip>D-22927</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chiesi Clinical Trial Site #0301</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chiesi Clinical Trial Site #0302</name>
      <address>
        <city>Leipzig</city>
        <zip>D-04357</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chiesi Clinical Trial Site #0104</name>
      <address>
        <city>Ferrara</city>
        <zip>44124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chiesi Clinical Trial Site #0101</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scichilone</name>
      <address>
        <city>Palermo</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chetta</name>
      <address>
        <city>Parma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chiesi Clinical Trial Site #0103</name>
      <address>
        <city>Pisa</city>
        <zip>56124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chiesi Clinical Trial Site #0102</name>
      <address>
        <city>Verona</city>
        <zip>37134</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>W. Boersma</name>
      <address>
        <city>Alkmaar</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. J. Vroegop</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. M. vd Berge</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. M. Broeders</name>
      <address>
        <city>Hertogenbosch</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chiesi Clinical Trial Site #0402</name>
      <address>
        <city>Barcelona</city>
        <zip>08026</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chiesi Clinical Trial Site #0401</name>
      <address>
        <city>Lugo</city>
        <zip>27003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
    <country>Canada</country>
    <country>China</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 24, 2014</study_first_submitted>
  <study_first_submitted_qc>April 24, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 25, 2014</study_first_posted>
  <last_update_submitted>October 16, 2017</last_update_submitted>
  <last_update_submitted_qc>October 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

